Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression (TOT-HER3)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04610528
Recruitment Status : Recruiting
First Posted : October 30, 2020
Last Update Posted : January 7, 2021
Sponsor:
Collaborator:
Daiichi Sankyo, Inc.
Information provided by (Responsible Party):
SOLTI Breast Cancer Research Group

Brief Summary:
Trial design This is a prospective, multicenter, single-arm, window-of-opportunity study evaluating the biological effect of patritumab deruxtecan in treatment naïve patients with HR-positive/HER2-negative early breast cancer, whose primary tumors are ≥1 cm by ultrasound evaluation. Patients will be enrolled in four cohorts according to the mRNA-based ERBB3 expression by central assessment. The objective of the study is to evaluate biological activity of patritumab deruxtecan in patients with treatment naïve early breast cancer. The primary endpoint is CelTIL score after one single-dose of U3-1402. A translational research plan is also included to provide biological information and to evaluate secondary and exploratory objectives of the study.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: U3 1402 Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
Actual Study Start Date : December 22, 2020
Estimated Primary Completion Date : September 30, 2021
Estimated Study Completion Date : April 30, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: U3-1402
U3-1402 is an antibody drug conjugate (ADC) comprising a recombinant fully human anti-human epidermal growth factor receptor (HER) 3 immunoglobulin G1 (IgG1) monoclonal antibody (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a). MAAA-1181a is released after internalization and leads to apoptosis of the target tumor cells by the inhibition of topoisomerase I
Drug: U3 1402
U3-1402 is an antibody drug conjugate (ADC) comprising a recombinant fully human anti-human epidermal growth factor receptor (HER) 3 immunoglobulin G1 (IgG1) monoclonal antibody (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
Other Name: Patritumab Deruxtecan




Primary Outcome Measures :
  1. CelTIL score [ Time Frame: baseline and after one dose of U3-1402 at Cycle 1 Day 21 ]

    Mean change in CelTIL score per central assessment in paired samples.

    CelTIL score = -0.8 × tumor cellularity (in %) + 1.3 × TILs (in %). The minimum and maximum unscaled CelTIL scores will be -80 and 130. This unscaled CelTIL score will then be scaled to reflect a range from 0 to 100 points.



Secondary Outcome Measures :
  1. CelTIL score [ Time Frame: baseline and after one dose of U3-1402 at Cycle 1 Day 21 ]
    Mean change in CelTIL score per central assessment in paired samples for each ERBB3 cohort

  2. ERBB3 levels vs. CelTIL score [ Time Frame: baseline and after one dose of U3-1402 at Cycle 1 Day 21 ]
    ERBB3 mRNA baseline levels and changes in CelTIL score for all patients and for each ERBB3 cohort

  3. HER3 IHC vs. CelTIL score [ Time Frame: baseline and after one dose of U3-1402 at Cycle 1 Day 21 ]
    HER3 IHC baseline levels and changes in CelTIL score for all patients and for each ERBB3 cohort

  4. PAM50 intrinsic subtypes vs. CelTIL score [ Time Frame: baseline and after one dose of U3-1402 at Cycle 1 Day 21 ]
    changes in CelTIL across the four PAM50 intrinsic subtypes.

  5. Complete Cell Cycle Arrest (CCCA) [ Time Frame: baseline and after one dose of U3-1402 at Cycle 1 Day 21 ]
    determined per central assessment by IHC Ki67< 2.7%

  6. ERBB3 mRNA expression vs. HER3 IHC [ Time Frame: baseline ]
    Correlation coefficients between both biomarkers

  7. safety and tolerability [ Time Frame: through study completion, an average of 65 days each patient ]
    Type, incidence, severity (as graded by the NCI CTCAE v. 5.0), seriousness and attribution to the study medications of AEs and any laboratory abnormalities.

  8. changes of HER3 expression. [ Time Frame: t baseline, at Day 3-Day 7 (optional), Cycle 1 Day 21 ]
    HER3 expression



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written ICF for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures.
  2. Premenopausal or postmenopausal women and men, age ≥ 18 years.
  3. ECOG Performance Status 0 - 1.
  4. Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast untreated and recently diagnosed, with all the following characteristics:

    • At least one lesion that can be measured in at least 1 dimension with ≥ 1 cm in largest diameter measured by ultrasound.
    • Absence of distant metastasis (M0) as determined by institutional practice.
    • In the case of a multifocal tumor (defined as the presence of two or more foci of cancer within the same breast quadrant), the largest lesion must be ≥ 1 cm and designated the "target" lesion for all subsequent tumor evaluations and biopsies.
  5. Patient must have biopsiable disease.
  6. Estrogen (ER)-positive and/or Progesterone (PgR)-positive and HER2-negative tumor by the most recent American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) guidelines: ER and PgR defined as IHC nuclear staining >1% and HER2 negative locally assessed.
  7. Ki67% ≥ 10% locally assessed (Dowsset et al. Journal of the National Cancer Institute, 103 (22), 1656-1664. 2011).
  8. Available pre-treatment FFPE core needle biopsy evaluable for PAM50 and ERBB3 mRNA expression. Minimal sample requirements are to have at least 2 tumor cylinders with a minimal tissue surface of 10 mm2 tissue, containing at least 50% tumor cells and having enough tissue to do at least 20 cuts of 4 μm each. Macrodissection is allowed when needed. If archival tissue is either insufficient or unavailable, a new biopsy from the pretreated tumor must be obtained. Patients whose tumor tissue is not evaluable for ERBB3 expression central testing are not eligible.
  9. Baseline LVEF ≥ 50% measured by echocardiography (ECHO) or Multiple Gate Acquisition (MUGA) scan
  10. Adequate organ function, as determined by the following laboratory tests prior to randomization:

    • Hematological

      • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
      • Platelet count ≥ 100 x 109/L
      • Hemoglobin ≥ 9 g/dL (red blood cell transfusion and/or erythropoietin allowed)
    • Renal

      o Serum creatinine ≤ 1.5 x upper limit of normal (ULN), or 24-hour creatinine clearance ≥ 60 mL/min for subject with creatinine levels > 1.5 x ULN. (Note: Creatinine clearance does not need to be determined if the baseline serum creatinine is within normal limits. Creatinine clearance should be calculated per institutional standard).

    • Hepatic

      • Serum bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for a subject with total bilirubin level > 1.5 x ULN
      • Aspartate aminotransferase (AST) ≤ 3 x ULN
      • Alanine aminotransferase (ALT) ≤ 3 x ULN
      • Coagulation International normalization ratio (INR) or prothrombin time (PT) ≤ 1.5 x ULN
      • Partial thromboplastin time (PTT) or activated PTT (aPTT) ≤ 1.5 x ULN
  11. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
  12. Female subject of childbearing potential should have a negative urine or serum pregnancy test within 7 days prior to enrollment. If urine pregnancy test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. Pregnancy testing does not need to be pursued in patients who are judged as postmenopausal before randomization, as determined by local practice, or who have undergone bilateral oophorectomy, total hysterectomy, or bilateral tubal ligation. Women of childbearing potential randomized to the treatment must use adequate contraception for the duration of protocol treatment and after 7 months after the study drug administration (see Appendix B).

Exclusion Criteria:

  1. Inoperable locally advanced or inflammatory (i.e., inoperable Stage III) breast cancer.
  2. Metastatic (Stage IV) breast cancer.
  3. Bilateral invasive breast cancer.
  4. Patients in whom a primary tumor excisional biopsy was performed.
  5. Any prior treatment for primary actual invasive breast cancer.
  6. Prior treatment with a HER3 antibody, topoisomerase I inhibitor, with an ADC which consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., DS-8201) and with a govitecan derivative (e.g., IMMU-132).
  7. Medical history of symptomatic congestive heart failure (New York Heart Association classes II-IV) or serious cardiac arrhythmia requiring treatment; myocardial infarction within 6 months prior to randomization or unstable angina.
  8. QT interval corrected using Fridericia's formula to > 450 millisecond (ms) in males and > 470 ms in females.
  9. Any factors that increase the risk of corrected QT (QTc) interval prolongation or risk of arrhythmic events, such as congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.
  10. Medical history of clinically significant lung diseases (e.g., interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or who are suspected to have these diseases by imaging at screening period.
  11. Clinically significant corneal disease.
  12. Major surgical procedure or significant traumatic injury within 28 days prior to randomization.
  13. Assessment by the investigator to be unable or unwilling to comply with the requirements of the protocol.
  14. History of other malignancy within the last 3 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other malignancies with an expected curative outcome.
  15. Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary or metabolic disease; wound healing disorders; ulcers; bone fractures).
  16. Concurrent, serious, uncontrolled infections or current known infection with HIV or active hepatitis B and/or hepatitis C.
  17. History of significant co-morbidities that, in the judgment of the investigator, may interfere with the conduction of the study, the evaluation of response, or with ICF.
  18. Known hypersensitivity to either the drug substance components (including an antibody, a drug-linker, or a topoisomerase I inhibitor) or inactive ingredients in the drug product or history of severe hypersensitivity reactions to other monoclonal antibodies.
  19. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder (i.e. pulmonary emboli within three months of the study enrollment, severe asthma, severe COPD, restrictive lung disease, pleural effusion etc.), and any autoimmune, connective tissue or inflammatory disorders with potential pulmonary involvement (i.e. rheumatoid arthritis, Sjögren's syndrome, sarcoidosis etc.), or prior pneumonectomy.
  20. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, grade ≤1 or baseline. Subjects with chronic grade 2 toxicities may be eligible per the discretion of the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04610528


Contacts
Layout table for location contacts
Contact: Juan Manuel Ferrero Cafiero 609691648 ferrerocafiero.juanmanuel@gmail.com

Locations
Layout table for location information
Spain
ICO Badalona Recruiting
Badalona, Barcelona, Spain
Principal Investigator: Mireia Margeli, MD         
Institut Català d'Oncologia Hospitalet Recruiting
Hospitalet de Llobregat, Barcelona, Spain
Principal Investigator: Sonia Pernas, MD         
Hospital Universitario de Canarias Recruiting
Tenerife, Islas Canarias, Spain, 38320
Principal Investigator: Josefina Cruz Jurado, MD         
Hospital Universitario de Fuenlabrada Recruiting
Fuenlabrada, Madrid, Spain
Principal Investigator: Juan Antonio Guerra, MD         
Hospital Universitari Vall d'Hebrón Recruiting
Barcelona, Spain, 08035
Contact: Oliveira         
Principal Investigator: Mafalda Oliveira, MD         
Hospital Clínic de Barcelona Recruiting
Barcelona, Spain, 08036
Principal Investigator: Aleix Prat, MD         
Centro Integral Oncológico Clara Campal (CIOCC) Recruiting
Madrid, Spain
Principal Investigator: Ana Luna, MD         
Hospital Universitario 12 de octubre Recruiting
Madrid, Spain
Principal Investigator: Pablo Tolosa         
Hospital Universitario Virgen del Rocio Recruiting
Sevilla, Spain
Principal Investigator: Javier Salvador Bofil, MD         
Hospital Clinico Universitario de Valencia Recruiting
Valencia, Spain
Principal Investigator: Juan Miguel Cejalvo, MD         
Sponsors and Collaborators
SOLTI Breast Cancer Research Group
Daiichi Sankyo, Inc.
Layout table for additonal information
Responsible Party: SOLTI Breast Cancer Research Group
ClinicalTrials.gov Identifier: NCT04610528    
Other Study ID Numbers: SOLTI-1805
2019-004964-23 ( EudraCT Number )
First Posted: October 30, 2020    Key Record Dates
Last Update Posted: January 7, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by SOLTI Breast Cancer Research Group:
her3
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases